Nanotherapeutic Approaches to Treat COVID-19-Induced Pulmonary Fibrosis.

ABSTRACT: There have been significant collaborative efforts over the past three years to develop therapies against COVID-19. During this journey, there has also been a lot of focus on understanding at-risk groups of patients who either have pre-existing conditions or have developed concomitant health conditions due to the impact of COVID-19 on the immune system. There was a high incidence of COVID-19-induced pulmonary fibrosis (PF) observed in patients. PF can cause significant morbidity and long-term disability and lead to death in the long run. Additionally, being a progressive disease, PF can also impact the patient for a long time after COVID infection and affect the overall quality of life. Although current therapies are being used as the mainstay for treating PF, there is no therapy specifical

SUBMITTER: Kanvinde S 

PROVIDER: S-EPMC10204512 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature